Related Experiment Videos
[Muscle relaxation using atracurium in porphyria variegata--case notes]
H Schmidt1, T Augenstein, H Böhrer
1Klinik für Anästhesiologie, Universität Heidelberg.
Summary
Atracurium, a muscle relaxant, was safely administered to a patient with variegate porphyria. This case study indicates no adverse effects or disease exacerbation, suggesting atracurium is a safe option for porphyria patients.
Area of Science:
- Anesthesiology and Pharmacology
- Metabolic Disorders
- Toxicology
Background:
- Variegate porphyria is a rare genetic disorder affecting heme synthesis.
- Anesthetic agents require careful selection in patients with porphyria due to potential risks.
- Atracurium is a non-depolarizing neuromuscular blocking agent used in anesthesia.
Observation:
- A single case of a patient with known variegate porphyria received atracurium (120 mg) for muscle relaxation.
- The patient's response to atracurium was closely monitored.
- Urinary porphyrin and precursor levels were assessed post-administration.
Findings:
- Administration of atracurium did not lead to an increase in urinary porphyrin or porphyrin precursor concentrations.
- No clinical exacerbation of variegate porphyria symptoms was observed in the patient.
- The patient tolerated the anesthetic agent without apparent adverse effects related to their porphyria.
Implications:
- This case suggests that atracurium may be a safe muscle relaxant for patients diagnosed with variegate porphyria.
- Further research and larger studies are warranted to confirm the safety profile of atracurium in this patient population.
- Anesthesiologists can consider atracurium as a potential option when managing patients with variegate porphyria, pending further evidence.